 "Pharmaceuticals, drugs, pharma industry, medical, health, lab")
Dr Reddy's Laboratories Wednesday announced the launch of Atomoxetine capsules used to treat attention-deficit hyperactivity disorder (ADHD) in the US market.
The Hyderabad-based company has received the approval from the US Food and Drug Administration (USFDA) to market its product which is a generic equivalent of Eli Lilly and Company's Straterra, Dr Reddy's Laboratories said in a statement.
As per the IMS Health sales data, the Strattera brand had US sales of around $304 million for the most recent 12 months ending in August 2018.
Shares of Dr Reddy's Laboratories were trading 1.87 per cent down at Rs 2,549 on the BSE.
